Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s stock price passed above its 200-day moving average during trading on Monday following a stronger than expected earnings report. The stock has a 200-day moving average of $0.81 and traded as high as $1.16. Brainstorm Cell Therapeutics shares last traded at $1.0854, with a volume of 71,972 shares.
The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06).
Brainstorm Cell Therapeutics Stock Down 17.2%
The firm has a market capitalization of $13.28 million, a PE ratio of -0.35 and a beta of 0.23. The business’s fifty day moving average price is $0.96 and its 200 day moving average price is $0.81.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical?stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Featured Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- Tesla’s Cybercab Launch Could Reshape Margins for Uber and Lyft
- Pony AI Stock Gains Traction as Robotaxi Fleet Expands Globally
- Amazon Plugs $18B Into the Southern Power Grid
- Speed Sells: Cerebras Cracks the Silicon Ceiling
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
